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evaluate whether the pricing and reimbursement decision of new drugs in Taiwan’s 
NHI to fulﬁll the transparency and the expectation of public beneﬁts.
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ASSESSING THE IMPACT AND VALUE OF HEALTH OUTCOMES 
PUBLICATIONS USING CITATION DATA FROM INDICES OF 
SCHOLARLY LITERATURE
Fisher DL1, Bakken R2
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OBJECTIVES: Clinical trial data are typically published in journals with a therapeutic 
area focus and accessed by researchers and health care providers (HCPs) for the 
purposes of sharing knowledge and improving outcomes for patients. Pharmacoeco-
nomic and health outcomes data are published for the same reasons, but often are 
most relevant to payers and other managed care decision makers. Yet there is limited 
knowledge of what factors make health outcomes publications most valuable to payers 
and HCPs and of how health outcomes decisions are inﬂuenced by publications. Our 
goal was to assess the impact of health outcome-related publications using literature 
citation data from two major web search engines that index scholarly literature. We 
envision that enhanced understanding of how health outcomes publications are sub-
sequently used may improve the quality of future publications and maximize useful-
ness to health care providers, payers, and patients. METHODS: In order to determine 
which types of papers were most read or most used to inform subsequent studies, we 
identiﬁed a sample of health outcomes papers published within the past 5 years and 
used Google Scholar and SciSearch to collect data on the number of times these 
publications were cited in subsequent research papers. RESULTS: Number of citations 
ranged from 0–57 per publication. Average number of citations was 10.2 per publica-
tion. Articles in therapeutically focused journals as well as cross-therapeutic health 
outcomes focused journals were frequently cited. CONCLUSIONS: These ﬁndings 
contribute to a growing understanding of the value of health outcomes publications 
for payers, health care decision-makers, and researchers in academia, government, and 
industry.
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IMPACT OF PHARMACEUTICAL REFORM AND ISSUES INVOLVED IN 
SOUTH KOREA’S NHI
Yang BM
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OBJECTIVES: To assess the impact of recent pharmaceutical reform in South Korea 
METHODS: Descriptive analysis RESULTS: The South Korean National Health 
Insurance (NHI) system recently introduced a reform in pharmaceutical reimburse-
ment, with the purpose of increasing rational resource use in drug spending. The new 
policy aims to take the cost-effectiveness and budget impact of newly introduced drugs 
into account in payment decisions, and to re-evaluate the economic rationale of for-
merly existing drugs in the NHI drug reimbursement list. Under the new policy, a new 
drug goes through two stages; the ﬁrst stage of reimbursement decision, and the second 
stage of price negotiation. That is, once a drug is determined to be in the reimburse-
ment list, then it will go through a price negotiation process. Recent data reveal that 
the new policy, called the PLSP(positive list system policy), somewhat reduced the rate 
of reimbursement listing and successful price negotiations. The impact of PLSP would 
be diverse, including economic effects, access to new drugs, and dynamic efﬁciency. 
It is also true that the new policy faces challenges and confronts a number of issues, 
such as availability of data, utility measurement, threshold, modeling, degree of evi-
dence use, and decision-making process. CONCLUSIONS: This paper will provide a 
review of the ﬁrst three years policy outcomes, and attempt to assss the Korean PLSP 
in terms of the challenges and issues mentioned above.
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OBJECTIVES: Health care providers across the globe are facing the signiﬁcant ﬁnan-
cial challenge of funding new, innovative and expensive medicines for populations 
who are living longer and demanding better care. This funding dynamic has not only 
increased immediate ﬁnancial pressures on health care systems but also raises the level 
of risk associated with uncertainty around both clinical efﬁcacy and budgetary impact. 
To address this, payers are raising market access hurdles and implementing new cost 
containment measures. In response, industry is developing new pricing and reimburse-
ment strategies. Risk sharing is one example of how payers are trying to ensure value 
for money. This study assesses whether risk-sharing agreements have the necessary 
components to become sustainable in the coming years. METHODS: Secondary 
research was conducted to categorize and assess the types of risk-sharing agreements 
currently in place. Primary research was then used to obtain both payer and industry 
insight about the success and shortcomings of risk sharing and to anticipate how 
risk-sharing agreements are likely to evolve in the future. RESULTS: Risk sharing is 
often a misnomer. While some risk sharing agreements are developed to address 
uncertainty around clinical evidence, the majority of them focus on reducing the 
ﬁnancial impact of new products independent of the clinical beneﬁt. CONCLUSIONS: 
This analysis suggests that there is no one perfect method of risk sharing. In order for 
risk sharing to transition from a trend into a sustainable method of ﬁnancing new 
therapies, a careful understanding of the risk a new therapy poses and how to best 
mitigate that risk is needed.
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A FRAMEWORK TO ASSIST PHARMACEUTICAL COMMERCIALIZATION 
TEAMS IN EFFICIENTLY ALLOCATING RESOURCES TO GENERATE 
EVIDENCE OF PRODUCT VALUE TO SUPPORT GLOBAL MARKET 
ACCESS ACROSS DIVERSE PAYER ENVIRONMENTS
Rizzo M, Zieses C
Double Helix Consulting US, New York, NY, USA
OBJECTIVES: A common goal among biopharmaceutical product development 
teams is incorporating market access considerations, e.g., clinical trial and outcomes 
data, health technology assessment (HTA) organization requirements, and pricing 
scenarios earlier in commercial planning in order to properly align product value with 
payer motivations. This research investigates the utility of a framework for commer-
cial teams to assess therapeutic category and product access opportunities; and to do 
so simultaneously in heterogeneous market access environments. The resulting graphi-
cal framework can be used by pharmaceutical ﬁrms to evaluate product positioning 
relative to various market access scenarios in order to inform product development 
and resource investment decisions. METHODS: A simpliﬁed payer value equation 
[(efﬁcacy + safety + burden of disease)/(product price—cost offsets)], is used to 
develop a graph to assess therapeutic areas and products relative to market access 
thresholds. Products are plotted using product value (y-axis) and a combination of 
disease burden and unmet medical need (x-axis). Market access thresholds are plotted 
as curves which represent the level of product innovation required to achieve various 
levels of market access. Movement across thresholds depicts signiﬁcant change in that 
product’s market access (e.g., non-reimbursed versus reimbursed). The position of 
market access thresholds can be estimated by deﬁning market access to existing 
products within individual payer systems. Analyzing product positioning simultane-
ously in multiple markets can be achieved by overlaying such graphs and aligning 
them along similar market access thresholds. RESULTS: This framework can be used 
to illuminate the level of product innovation required to meet the increasingly strin-
gent requirements for market access and inform ﬁrms’ investment decisions. CON-
CLUSIONS: Market access environments are complex and dynamic. Assessing 
therapeutic category and the attributes of new medicines relative to market access 
thresholds can inform pharmaceutical ﬁrms’ strategies to generate evidence of product 
value that are aligned with payer priorities.
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1ISPOR local chapter Slovakia, Bratislava, Slovak Republic, 2Medispektrum, Bratislava, Slovak 
Republic, 3Ministry of Health, Bratislava, Slovak Republic, 4Ministry of Finance, Bratislava, 
Slovak Republic
OBJECTIVES: To look into the impact of the drug policies in the Slovak Republic in 
2006–2009. To evaluate drug policy in terms of drugs’ accessibility, extent of patients’ 
co-payments and introduction of innovative drugs. To compare market developments 
in Slovakia to its neighbors, and EU/OECD countries. METHODS: We calculated the 
impact of several regulatory measures on the size of the market and health insurance 
expenditure: a) Lowering the VAT for drugs from 19% to 10% b) ﬂat price cut (−6.6% 
and −7.4%) c) introduction of degressive mark-up for wholesalers and for pharmacies 
d) two rounds of the international reference pricing.The data on drugs consumption 
were from national databases IMS Health and Pharmadata Ltd. We paired these data 
with reimbursement lists published by Slovak Ministry of Health. We compared trends 
in the Slovak drug market to market trends in neighboring countries and to OECD/
EU markets. RESULTS: In 2006 through 2009, the actual calculated savings on 
publicly-covered drugs reached EUR 160 mil due to the ﬂat price cuts, 385 mil due 
to two international reference pricing rounds and EUR 40 mil due to the degressive 
mark-up. The total volume of the Slovak market in 2009 was 31080 mil in manufac-
turers’ prices, in a country of 5,4 mil inhabitants. Consumption of drugs per capita 
reached app. 3200. CONCLUSIONS: Slovak drug policy was able to signiﬁcantly 
decrese the share of pharma expenditure in total health expenditure while increasing 
access new to drugs. Annual growth of the market in the period averaged 6.3% (1.4% 
in 2009), share of drugs in total health expenditure fell from 37% to 27%%, more 
than 100 new molecules s entered the market, and co-payments are astable app. 12% 
of total drug expenditure. We noticed this trend of decreasing market growth also in 
west European countries, but in middle-east European countries the growth of drug 
market was increasing by more than 10% also in 2009.
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OBJECTIVES: The objective of this study is to empirically investigate how the medical 
loss ratio (MLR) changes over time and what factors contribute to that change for 
patients enrolled to Medicare Advantage Special Need Plans. METHODS: We used a 
data supplied by a Medicare Advantage Special Need Plan, which include enrollees’ 
monthly premiums and expenses. The data also provide enrollees’ demographic infor-
mation and CMS risk scores and information regarding facilities and providers par-
ticipating in this plan. We deﬁned MLR as the total amount of revenues from health 
insurance premiums that is spent to pay for the medical services covered by the plan. 
Next, we created a panel data structure and deployed multilevel econometric models 
in our analysis. Finally, we used Hausman test to evaluate the signiﬁcance of ﬁxed-
effect estimators versus the alternative random-effect estimators. RESULTS: We found 
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the following outcomes after controlling for individuals’ observed and unobserved 
characteristics together with their CMS risk scores: 1) Adjusted MLR spikes up at the 
same time as the share of enrollees who die also spikes upward; (2) Adjusted expenses 
paid by the plan on behalf of enrollees who died while enrolled are much higher than 
the CMS payments to the plan for the same enrollees in the month of death and in 
the 4 to 6 months prior to death; and 3) We found that death rates in each calendar 
month explain about 30 to 40% of adjusted MLR. CONCLUSIONS: The results show 
that Medicare Part A utilization and expenditures have a limited role in the increasing 
trend of adjusted MLR for beneﬁciaries who survive through the enrollment period. 
However, we ﬁnd a positive, stronger and statistically signiﬁcant correlation between 
inpatient visits and the expenses for enrollees who died while enrolled. The correlation 
remains signiﬁcant up to 24 months prior to the death of an enrollee.
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OBJECTIVES: In Canada, the CDR conducts health technology assessments and 
provides funding recommendations to participating jurisdictions. These recommenda-
tions are publically available but little research has been conducted to understand 
the rationale behind these decisions. Furthermore, the acceptable ICER for the CDR 
is not published but is generally perceived to be $50,000/QALY. This study was 
conducted to analyze published CDR recommendations to determine if speciﬁc factors 
inﬂuence decision-making. METHODS: For this abstract, four variables were con-
sidered for 143 recommendations (December 2003 to October 2009). These variables 
include manufacturer-submitted ICER, ﬁrst-in-class status, therapeutic categories, 
and request for reconsiderations. RESULTS: Thirty-seven of 143 CDR recommenda-
tions reported ICER values and were analyzed. The average ICER was $47,900 ± 
29,100/QALY (N = 20) for “List” recommendations and $91,400 ± 52,300/QALY 
(N = 17) for “Do not list” recommendations (p < 0.05). A trend towards statistical 
signiﬁcance for an effect of ﬁrst-in-class on receiving negative recommendation was 
observed (Fisher’s exact test, p = 0.0873). There appeared to be an overall effect 
of therapeutic category on recommendation (χ2: 36.213, df: 11, p < 0.0001). An 
effect of requests for reconsideration on recommendation outcome was also observed 
(Fisher’s exact test, p < 0.0001). CONCLUSIONS: From the pharmacoeconomics 
perspective, the average ICER of $47,900/QALY is in alignment with the perceived 
limit, although majority of reviews did not have a reported ICER. Nonetheless, 
considerable variation in the ICER indicated additional factors inﬂuence CDR 
decision-making. Being ﬁrst-in-class had small but non-signiﬁcant inﬂuence on CDR 
recommendation. Therapeutic category had signiﬁcant inﬂuence on recommendations 
although the sample size was small and further investigation is needed to determine 
the cause. Finally, requests for reconsideration did little to inﬂuence the initial CDR 
recommendation. The overall ﬁndings suggested that while the ICER may be an 
important input into the decision-making process, careful examination of other 
factors will be needed to further understand the relative inﬂuence of the ICER on 
ﬁnal CDR recommendations.
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INNOVATIVE PRICING AGREEMENTS IN UK NICE SUBMISSIONS
Costello S, Haynes S, Kusel J
Costello Medical Consulting Limited, Cambridge, UK
OBJECTIVES: In order to meet the cost-effectiveness requirements of the National 
Institute for Health and Clinical Excellence (NICE), manufacturers are increasingly 
utilizing innovative pricing agreements (IPAs). This research aims to identify all such 
agreements from published NICE appraisals and to provide recommendations to 
pharmaceutical companies on their utility. METHODS: All completed NICE technol-
ogy appraisals published from 2006 to 2009 were reviewed and any submission in 
which the guidance included an IPA was identiﬁed. An IPA was deﬁned as the manu-
facturer providing a pre-deﬁned reduction of the overall cost of treatment based on 
risk sharing or rebate schemes. RESULTS: The inclusion of IPAs in NICE guidance 
is increasing over time. Of 18 appraisals published in 2006 none included an IPA. 
There was an IPA element in 5% (1/21) appraisals in 2007, increasing to 7% of 
appraisals (2/27) in 2008, and 22% (4/18) in 2009. Of the 7 IPAs identiﬁed from 
2006 to 2009, 5 were for oncology products, the others being for psoriasis and age-
related macular generation. The form of the IPAs could be broadly categorized into 
1) a rebate across a speciﬁc patient population (N = 3); 2) drug provided free for 
patients remaining on treatment beyond a speciﬁc point (N = 2); 3) provision of free 
ﬁrst cycle of treatment (N = 1) and 4) cost matched to existing treatment (N = 1). 
IPAs were included through initial proposals to the Department of Health by the 
manufacturer (N = 3), as part of the revised manufacturer’s model following the initial 
review (N = 3) and through proposals by the NICE committee (N = 1). CONCLU-
SIONS: Pharmaceutical companies are increasingly using innovative price agreements 
in their NICE submissions. Such agreements are mutually beneﬁcial and acceptable to 
both parties and provide an opportunity for companies to demonstrate their conﬁ-
dence in the value claims of speciﬁc therapies.
HEALTH CARE USE & POLICY STUDIES – Health Care Research & 
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THE STATE OF HEALTH ECONOMICS AND PHARMACEOCONOMICS 
EVALUATION RESEARCH IN NIGERIA: A SYSTEMATIC REVIEW
Gavaza P, Rascati K, Oladapo AO, Khoza S
The University of Texas at Austin, Austin, TX, USA
OBJECTIVES: The study was conducted to describe the characteristics and quality of 
health economic (including pharmacoeconomics) evaluation research studies related 
to Nigeria. METHODS: A literature review was conducted to identify health economic 
evaluation articles. Main databases (e.g., PUBMED, MEDLINE) were used to search 
for economic analyses. The study included only original economic evaluations that 
pertained to Nigeria, addressed a health-related topic (e.g., pharmacy) and were 
complete peer-reviewed publications in the English language. Two reviewers indepen-
dently evaluated and scored each article in the ﬁnal sample using a data collection 
form. RESULTS: The 44 identiﬁed articles were published in 34 different journals 
mostly based outside of Nigeria between 1988 and 2009. On average, each article 
was written by four authors. Most (98%) ﬁrst authors had medical/clinical training 
and resided in Nigeria (75%) at the time of publication of the study. Based on a 1 to 
10 scale, with 10 indicating the highest quality, the mean quality score for all studies 
was 7.29 (SD = 1.21) and 59 percent of the articles were of fair quality (score 5–7). 
The quality of articles was statistically signiﬁcantly related (p < 0.05) to the country 
of residence of primary author (non-Nigeria = higher), the country of journal 
(non-Nigeria = higher), primary objective of the study (economic evaluation as the 
objective = higher), and type of economic analysis conducted (full economic evalua-
tions = higher). The quality of the articles was not signiﬁcantly related to the sample 
size, type of data (primary vs secondary), number of authors, type of publication, year 
of publication, study perspective and primary health intervention (p > 0.05). CON-
CLUSIONS: The conduct of health economics (including pharmacoeconomics) evalu-
ation research in Nigeria is limited and about two-thirds of published articles were of 
fair quality. More and better quality health economics research in Nigeria is 
warranted.
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OBJECTIVES: This study aimed to summarize the current status and desired compo-
nents of pharmacoeconomics and outcomes research PhD programs. METHODS: 
Using the educational directory on the ISPOR website, 32 PhD programs were identi-
ﬁed and contacted. Programs’ participation in an online survey was requested if their 
program focused on pharmacoeconomics, outcomes research or related ﬁelds. The 23 
question survey asked for speciﬁc information about their program, faculty, staff and 
students as well as their insight on factors important to such training. RESULTS: Of 
the 32 programs contacted, 14 (44%) responded, with two stating that their program 
did not ﬁt the inclusion criteria. Of the ﬁve programs offering degrees in pharmaceuti-
cal outcomes or economics speciﬁcally, 1994 was the earliest year of establishment 
and 2001 the most recent. The remaining programs provided such training within 
broader and more established programs. On average, programs had seven full-time 
faculty, four staff and 15 current PhD students. When asked about the ideal number 
for a program’s success, 8 full-time faculty and 17 students were desired. Historically, 
51% of students had a previous Master’s degree, 36% had a professional degree and 
about 16% had a Bachelor’s degree only. The mean time for completion of coursework 
was 2.7 years and 4.9 years to graduation. After graduation, 32% of students take a 
job in academia, 41% take a job in industry and 10% take a post-doctoral position. 
When asked about factors contributing to a program’s success, reputation of faculty’s 
research was thought to be most important. For students entering a PhD program in 
this ﬁeld, faculty’s mentoring experience and reputation was considered most impor-
tant. CONCLUSIONS: Programs offering speciﬁc training in this ﬁeld have only been 
in existence about 15 years. Programs appear to be growing, as desired number of 
faculty and students are higher than average numbers existing presently.
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PHARMACIST’S PERSPECTIVE ON RECENT LABELING CHANGES 
REQUIRED BY FDA FOR OVER-THE-COUNTER INTERNAL ANALGESIC, 
ANTIPYRETIC AND ANTIRHEUMATIC DRUGS
Bhattacharya R, Shah A, Kadakia A, Gupta P, Sansgiry SS
University Of Houston, Houston, TX, USA
OBJECTIVES: The US Food and Drug Administration (FDA) proposed labeling 
changes to be implemented by April 29, 2010 that would improve inappropriate 
and excessive use of over-the-counter (OTC) internal analgesic, antipyretic and anti-
rheumatic drugs (IAAA). This study examined the attitude and knowledge of phar-
macists about these labeling changes as pharmacists regularly advise on such products 
to consumers. METHODS: A prospective, cross-sectional study was conducted by 
surveying pharmacists working in a 15 mile radius of the Texas Medical Center. 
The survey instrument consisted of a 25 item questionnaire. Cronbach’s alpha (0.89) 
was used to assess the internal consistency of the instrument. Two-sided studentized 
t-test (μ = 3, α = 0.05) and descriptive statistics were used to analyze pharmacist’s 
attitude and awareness respectively for each individual parameter pertaining to the 
labeling changes. RESULTS: A total of 51 (out of 70) community pharmacist par-
